A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 9
- 主要终点
- Maximum tolerated dose and dose-limiting toxicities as determined in Part A.
研究概览
简要总结
DKN-01 is a humanized monoclonal antibody (Mab) with neutralizing activity against Dkk-1 and is being developed as an anti-neoplastic agent. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of DKN-01 in combination with gemcitabine and cisplatin in patients with carcinoma primary to the intra- or exta-hepatic biliary system or gallbladder.
详细描述
In Part A, escalating doses of DKN-01 will be administered to different cohorts of patients to evaluate safety and dose limiting toxicities (DLTs) and to establish the maximum tolerated dose of DKN-01 when administered in combination with gemcitabine and cisplatin.
Part B is an expansion cohort in which patients are treated at the MTD of DKN-01 (or highest dose tested if the MTD is not defined) to further characterize safety, tolerability, pharmacokinetics and efficacy within the defined patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder.
- •Patient must have sufficient tumor tissue available for submission.
- •For patients who have received prior cryotherapy, radiofrequency ablation, radioembolization, ethanol injection, transarterial chemoembolization (TACE) or photodynamic therapy, at least 28 days must have elapsed since that therapy, and lesions that have not been treated with local therapy must be present and measurable.
- •Patients may have received prior adjuvant chemotherapy with gemcitabine with or without cisplatin, as long as 6 months have elapsed since last treatment.
- •Patients must have one or more tumors measurable on radiographic imaging as defined by RECIST.
- •ECOG PS of 0 or
- •Patients with an ECOG PS of 2 may be entered upon review and approval of the medical monitor.
- •Estimated life expectancy of at least 3 months.
- •Disease-free of active second/secondary or prior malignancies for ≥ 2 years with the exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or breast.
- •Adequate hematological, renal, hepatic and coagulation laboratory test results.
- •Women of child bearing potential and men must agree to use adequate contraception during the study and for 6 months after their last dose of study drug.
- •Available for the duration of the study and are willing to follow study-specific procedures.
- •Provide written informed consent
排除标准
- •New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia.
- •Have Fridericia-corrected QT interval (QTcF) > 470 msec (female) or > 450 (male), or history of congenital long QT syndrome.
- •Active, uncontrolled bacterial, viral, or fungal infections.
- •Known to be human immunodeficiency virus (HIV) positive or has untreated, active hepatitis B.
- •History of major organ transplant.
- •History of an autologous/allogenic bone marrow transplant.
- •Serious nonmalignant disease.
- •Pregnant or nursing.
- •History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are symptomatic and clinically significant.
- •Symptomatic central nervous system (CNS) malignancy or metastasis.
- •Clinically significant peripheral neuropathy
- •Known osteoblastic bony metastasis.
- •Treatment with surgery or chemotherapy within 21 days prior to study entry or radiation within 14 days of study entry.
- •Previously treated with an anti-Dkk-1 therapy.
- •Other exclusions apply
研究组 & 干预措施
150 mg DKN-01 Part A
Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: DKN-01 (Drug)
150 mg DKN-01 Part A
Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: gemcitabine (Drug)
150 mg DKN-01 Part A
Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: cisplatin (Drug)
300 mg DKN-01 Part A
Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: DKN-01 (Drug)
300 mg DKN-01 Part A
Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: gemcitabine (Drug)
300 mg DKN-01 Part A
Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: cisplatin (Drug)
MTD mg DKN-01 Part B
Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: DKN-01 (Drug)
MTD mg DKN-01 Part B
Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: gemcitabine (Drug)
MTD mg DKN-01 Part B
Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
干预措施: cisplatin (Drug)
结局指标
主要结局
Maximum tolerated dose and dose-limiting toxicities as determined in Part A.
时间窗: End of Cycle 1 (Day 21)
Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.03).
Composite Safety parameters as assessed by new or changing physical examinations, vital signs, electrocardiograms (ECGs), clinical laboratories, concomitant medication reviews, and assessment of adverse events.
时间窗: Parts A and B: at a minimum Days 1, 8, 15 of each treatment cycle.
次要结局
- Pharmacokinetics - AUC(Cycle 1 - Days 1 and 8, Cycle 2 - Day 1)
- Pharmacokinetics - Cmax(Cycle 1 - Days 1 and 8, Cycle 2 - Day 1)
- Pharmacokinetics - Tmax(Cycle 1 - Days 1 and 8, Cycle 2 - Day 1)
- Efficacy - Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1)(At baseline, prior to the start of Cycle 3, and every 2 cycles thereafter until disease progression or death)